We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-0.23%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$238M
AUM Growth
-$45.5M
Cap. Flow
-$26.2M
Cap. Flow %
-11.03%
Top 10 Hldgs %
62.29%
Holding
58
New
11
Increased
7
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$18.1M
2
RLMD icon
Relmada Therapeutics
RLMD
+$8.98M
3
PYXS icon
Pyxis Oncology
PYXS
+$7.76M
4
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.81M
5
VRDN icon
Viridian Therapeutics
VRDN
+$3.39M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.9M
2
BLU
BELLUS Health Inc.
BLU
+$9.84M
3
CLSD
Clearside Biomedical
CLSD
+$7.9M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.75M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.28M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
2 Financials 5.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
26
EyePoint Inc
EYPT
$1.03B
$2.98M 1.25%
243,072
-126,791
-34% -$1.71M
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.93M 1.23%
+20,000
New +$3.11M
ALDX icon
28
Aldeyra Therapeutics
ALDX
$96.5M
$2M 0.84%
+500,000
New +$3.81M
SRRA
29
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.49M 0.63%
+68,500
New +$1.51M
ACRS icon
30
Aclaris Therapeutics
ACRS
$888M
$1.43M 0.6%
98,000
-42,839
-30% -$649K
GOSS icon
31
Gossamer Bio
GOSS
$86.9M
$1.35M 0.57%
119,843
-95,157
-44% -$1.13M
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
$1.26M 0.53%
+21,500
New +$1.61M
GRTX
33
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.21M 0.51%
+262,500
New +$868K
JNCE
34
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.06M 0.45%
+127,500
New +$1.05M
NUVB icon
35
Nuvation Bio
NUVB
$2.22B
$172K 0.07%
+90,832
New +$835K
ALLK
36
DELISTED
Allakos
ALLK
– –
-17,500
Closed -$1.85M
ALT icon
37
Altimmune
ALT
$589M
– –
-150,000
Closed -$1.7M
AVDL
38
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-250,000
Closed -$2.45M
BCYC
39
Bicycle Therapeutics
BCYC
$277M
– –
-38,184
Closed -$1.59M
CABA icon
40
Cabaletta Bio
CABA
$442M
– –
-302,926
Closed -$3.68M
CCCC icon
41
C4 Therapeutics
CCCC
$400M
– –
-21,000
Closed -$938K
CLSD
42
DELISTED
Clearside Biomedical
CLSD
– –
-87,751
Closed -$7.9M
ELAN icon
43
Elanco Animal Health
ELAN
$13.1B
– –
-29,000
Closed -$925K
GYRE icon
44
Gyre Therapeutics
GYRE
$695M
– –
-48,667
Closed -$1.5M
KRYS icon
45
Krystal Biotech
KRYS
$9.64B
– –
-72,551
Closed -$3.79M
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-90,832
Closed -$242K
NVAX icon
47
Novavax
NVAX
$1.27B
– –
-2,315
Closed -$480K
OLMA icon
48
Olema Pharmaceuticals
OLMA
$1.01B
– –
-150,500
Closed -$4.15M
RNAM
49
DELISTED
Avidity Biosciences
RNAM
– –
-60,000
Closed -$1.48M
RNAC icon
50
Cartesian Therapeutics
RNAC
$245M
– –
-34,156
Closed -$4.26M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return

Acuta Capital Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Acuta Capital Partners held 58 positions worth $238M, down 16% from $283M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $26.2M in Q4 2021, closing 22 positions and reducing 11 holdings. Its most notable exit was Clearside Biomedical, an estimated $7.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Relmada Therapeutics worth $9.1M.

  • Acuta Capital Partners's largest Q4 2021 buy was Relmada Therapeutics: 404,000 shares worth $9.1M.
  • Acuta Capital Partners added most to Apellis Pharmaceuticals in Q4 2021, an estimated $18.1M increase.
  • Acuta Capital Partners's biggest Q4 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $10.9M.
  • Acuta Capital Partners fully exited Clearside Biomedical in Q4 2021, selling an estimated $7.9M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $238M portfolio in Q4 2021.
  • Acuta Capital Partners opened 11 new positions and closed 22 in Q4 2021.
  • Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $238M.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.